AKT1 and glioma: Concurrently, γ-secretase inhibitor MK-0752 downregulates Notch1/Hes1 signaling, reducing AKT/mTOR phosphorylation and CXCR4 expression, thereby attenuating glioma stem cell aggressiveness (107).